Covid-19: SEC nod for Bharat Biotech to conduct Phase III booster dose study for its intranasal vaccine
The Subject Experts Committee (SEC) of the Drug Controller General of India (DGCI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine. The company will now conduct trials for its intranasal vaccine (BBV154).
READ MORE:
Other Biotech Videos
AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence
USV | Take heart: Steering preventive strategies for charting a journey towards cardiac wellness
Beat Diabetes With Lifestyle Modification
Serum to double investment in Biocon's unit to $300 mn; aim to generate higher EBITDA going ahead: Kiran Mazumdar-Shaw
India is stepping up genome sequencing of COVID 19 positive samples amid growing outbreaks in China, Japan and South Korea
